Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00504634 | Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | completed | Phase 2 | 166 | University of AarhusOTHER | 3 | Sep 8, 2011 | clinicaltrials |
| NCT00113932 | UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma | completed | Phase 2 | 140 | University of ArkansasOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00428077 | Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 4 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00504803 | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease | completed | Phase 2 | 30 | University of LiegeOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00693927 | Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) | completed | Phase 2 | 54 | University of LiegeOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT01051115 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease(D'ACCORD) | unknown | Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 31, 2011 | clinicaltrials |
| NCT01423175 | ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS(ClAraC-SCT) | unknown | Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00004908 | Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Northwestern UniversityOTHER | 1 | Aug 26, 2011 | clinicaltrials |
| NCT00107614 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients | terminated | Phase 2 | 12 | University of ArkansasOTHER | 1 | Aug 26, 2011 | clinicaltrials |
| NCT01423032 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 96 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin(FB-ATG) | terminated | Phase 2 | 20 | King's College Hospital NHS TrustOTHER | 1 | Aug 17, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00760084 | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 10 | Eisai Inc.INDUSTRY | 1 | Aug 8, 2011 | clinicaltrials |
| NCT00263484 | Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma(dtZ) | completed | Phase 2 | 56 | Gleneagles HospitalOTHER | 3 | Jul 21, 2011 | clinicaltrials |
| NCT00002778 | Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00003561 | Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 6 | CancerCare ManitobaOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00797472 | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | unknown | Phase 2 | 120 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab | terminated | Phase 2 | 1 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | withdrawn | Phase 2 | 37 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00089037 | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT00768339 | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | terminated | Phase 1 / Phase 2 | 25 | Aegera TherapeuticsINDUSTRY | 2 | Jul 13, 2011 | clinicaltrials |
| NCT01018069 | AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | terminated | Phase 2 | 60 | Aegera TherapeuticsINDUSTRY | 3 | Jul 13, 2011 | clinicaltrials |
| NCT01385891 | Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children(CLOVE) | completed | Phase 2 / Phase 3 | 40 | Istituto Giannina GasliniOTHER | 1 | Jul 8, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00165295 | Sildenafil Citrate in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00004084 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | completed | Phase 1 / Phase 2 | 21 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00004107 | Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 18 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00561743 | A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 50 | Janssen-Ortho Inc., CanadaINDUSTRY | 0 | Jun 21, 2011 | clinicaltrials |
| NCT00283439 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | completed | Phase 1 / Phase 2 | 39 | AmgenINDUSTRY | 0 | Jun 20, 2011 | clinicaltrials |
| NCT01116128 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients(D-MP) | terminated | Phase 2 | 8 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 14, 2011 | clinicaltrials |
| NCT00002681 | Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma | completed | Phase 1 / Phase 2 | 25 | Roger Williams Medical CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01370434 | Two Cycles of PAD Combination by AHCT in MM(PADinMM) | completed | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00112775 | BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | unknown | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 7, 2011 | clinicaltrials |
| NCT00270049 | Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | completed | Phase 2 | 195 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00042822 | FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00216697 | An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy | completed | Phase 2 | 13 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00806767 | Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer | completed | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00840684 | Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 135 | Institut Paoli-CalmettesOTHER | 1 | May 13, 2011 | clinicaltrials |
| NCT00002504 | Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00049413 | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00559624 | Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients | completed | Phase 1 / Phase 2 | 40 | Advancell - Advanced In Vitro Cell Technologies, S.A.INDUSTRY | 3 | May 10, 2011 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00339196 | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | completed | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 9, 2011 | clinicaltrials |
Data updated 24 days agoSource updated Sep 15, 2011source: clinicaltrials